Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | DRD1 | P21728 | 2/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | DRD5 | P21918 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | HTR5A | P47898 | 2/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12203628 | 0.85 | CYP2A6 (0.46) | CYP1A2DRD2DRD1DRD4DRD5 | |
| SCHEMBL14519448 | 0.85 | CYP2A6 (0.46) | CYP1A2DRD2DRD1DRD4DRD5 | |
| SCHEMBL4285081 | 0.77 | CYP1A2 (0.48) | CYP1A2DRD2DRD1DRD4DRD5 | |
| SCHEMBL4042214 | 0.72 | CYP1A2 (0.43) | CYP1A2DRD2DRD1DRD4DRD5 | |
| SCHEMBL5190200 | 0.72 | CYP1A2 (0.43) | CYP1A2DRD2DRD1DRD4DRD5 | |
| SCHEMBL29392481 | 0.72 | CYP1A2 (0.43) | CYP1A2DRD2DRD1DRD4DRD5 | |
| SCHEMBL7337805 | 0.72 | CYP1A2 (0.39) | CYP1A2DRD2DRD1DRD4DRD5 | |
| SCHEMBL109650 | 0.71 | CYP1A2 (0.62) | CYP1A2DRD2DRD1DRD4DRD5 | |
| SCHEMBL29881712 | 0.71 | — | — | |
| SCHEMBL22081972 | 0.71 | CYP1A2 (0.62) | CYP1A2DRD2DRD1DRD4DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9411226-B2 | Chemically amplified resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2016-08-09 | — | — | US | disclosed |
| US-20140163028-A1 | INHIBITION OF ACTIVATED CDC42-ASSOCIATED KINASE 1 | INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER (US) | 2014-06-12 | — | — | US | disclosed |
| US-8658655-B2 | Inhibition of activated cdc42-associated kinase 1 | FOX CHASE CANCER CENTER (US) | 2014-02-25 | — | — | US | disclosed |
| US-20120245173-A1 | INHIBITION OF ACTIVATED CDC42-ASSOCIATED KINASE 1 | Reaction Biology Corporation (US) | 2012-09-27 | — | — | US | disclosed |
| US-7348333-B2 | Cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists | AVENTIS PHARMA S.A. (FR) | 2008-03-25 | — | — | US | disclosed |
| US-20080021055-A1 | Novel cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists | AVENTIS PHARMA S.A. | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021055-A1 | Novel cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists | ADGRF1, ADGRE5, CALCR | CYP1A2 2943/4885DRD2 663/4885DRD1 841/4885 |
| US-20120245173-A1 | INHIBITION OF ACTIVATED CDC42-ASSOCIATED KINASE 1 | TNK2, CDC42BPA, CDC42BPG | CYP1A2 4748/4885DRD2 4503/4885DRD1 4315/4885 |
| US-20140163028-A1 | INHIBITION OF ACTIVATED CDC42-ASSOCIATED KINASE 1 | TNK2, CDC42BPA, CDC42BPG | CYP1A2 4748/4885DRD2 4503/4885DRD1 4315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.